Traws Pharma

TRAW

Biotechnology · Healthcare

Price

$0.53

-0.01 (-1.46%)

Market Cap

$8.1M

Exchange

NASDAQ Global Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+1144.1% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 673K (2021) → 8.4M (2025)

Traws Pharma is a small biotechnology company focused on developing antiviral drugs to treat serious infectious diseases. Its main targets include influenza and other respiratory viruses that can be life-threatening, especially for vulnerable patients like the elderly or immunocompromised. The company is in the clinical-stage, meaning it does not yet sell approved products to the public.

Because Traws Pharma has no approved drugs on the market, it currently generates little to no revenue and operates at a loss — which is typical for early-stage biotech companies. It funds its research primarily through equity financing and partnerships rather than product sales. The company operates mainly in the United States. Its main risk is the uncertainty of clinical trials: if its drug candidates fail to prove safe and effective, or fail to win regulatory approval from the FDA, the company could run out of funding before reaching commercialization.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-381.8% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$12M/ year

↓ Declining (-91% vs prior year)

435.2% of revenue

24.2x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

22.9%ownership

Insiders own a meaningful stake in the company

Cash Runway

~4 months

$3M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Traws Pharma has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial